Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | PDE7A | Q13946 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | APOBEC3G | Q9HC16 | 2/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KDM4A | O75164 | 1/20 | 0.35 |
| ▸ | TDP2 | O95551 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3044512 | 0.87 | PDE7A (0.37) | LMNAALDH1A1PDE7ASMN1; SMN2HSD17B10 | |
| SCHEMBL5833149 | 0.84 | PDE7A (0.56) | LMNAALDH1A1PDE7ASMN1; SMN2MAPT | |
| SCHEMBL3838786 | 0.84 | PDE7A (0.35) | LMNAALDH1A1PDE7ASMN1; SMN2HSD17B10 | |
| SCHEMBL3055047 | 0.84 | GPR35 (0.39) | LMNAALDH1A1PDE7ASMN1; SMN2HSD17B10 | |
| SCHEMBL28351783 | 0.84 | LMNA (0.46) | LMNAALDH1A1PDE7ASMN1; SMN2MAPT | |
| SCHEMBL4368894 | 0.79 | ALDH1A1 (0.53) | ALDH1A1SMN1; SMN2PKMKMT2ATSHR | |
| SCHEMBL2461047 | 0.79 | POLB (0.59) | LMNAALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL31163274 | 0.79 | POLB (0.59) | LMNAALDH1A1SMN1; SMN2MAPTMEN1 | |
| SCHEMBL9635033 | 0.79 | APOBEC3G (0.55) | ALDH1A1SMN1; SMN2MAPTAPOBEC3GMEN1 | |
| SCHEMBL11554587 | 0.77 | SIRT1 (0.53) | ALDH1A1SMN1; SMN2HSD17B10MAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037379-B2 | CD71 binding fibronectin type III domains | Aro Biotherapeutics Company (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4374005-A2 | HUMAN FIBRONECTIN TYPE III PROTEIN SCAFFOLDS | ARO Biotherapeutics Company (US) | 2024-05-29 | — | — | EP | disclosed |
| WO-2024086741-A2 | CD71 BINDING FIBRONECTIN TYPE III DOMAINS | Aro Biotherapeutics Company (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240100129-A1 | Serum Albumin-Binding Fibronectin Type III Domains | JANSSEN BIOTECH, INC. | 2024-03-28 | — | — | US | disclosed |
| US-11932680-B2 | CD8A-binding fibronectin type III domains | JANSSEN BIOTECH, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| EP-4323409-A2 | CD71 BINDING FIBRONECTIN TYPE III DOMAINS | ARO Biotherapeutics Company (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-3808767-B1 | BISPECIFIC EGFR/C-MET ANTIBODIES | JANSSEN BIOTECH INC (US) | 2023-12-06 | — | — | EP | disclosed |
| US-11833190-B2 | Serum albumin-binding fibronectin type III domains | JANSSEN BIOTECH, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230330239-A1 | EPCAM BINDING FIBRONECTIN TYPE III DOMAINS | Aro Biotherapeutics Company | 2023-10-19 | — | — | US | disclosed |
| US-11788081-B2 | Protein macrocyclization | STICHTING VU (NL) | 2023-10-17 | — | — | US | disclosed |
| US-20140141000-A1 | Bispecific EGFR/C-Met Antibodies | JANSSEN BIOTECH, INC. (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140018519-A1 | Stabilized Fibronectin Domain Compositions, Methods and Uses | JANSSEN BIOTECH, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| WO-2013177398-A2 | NON-NATURAL CONSENSUS ALBUMIN BINDING DOMAINS | JANSSEN BIOTECH, INC. (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130316952-A1 | Non-Natural Consensus Albumin Binding Domains | JANSSEN BIOTECH, INC. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8569227-B2 | Stabilized fibronectin domain compositions, methods and uses | JANSSEN BIOTECH, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| WO-2013049275-A1 | FIBRONECTIN TYPE III REPEAT BASED PROTEIN SCAFFOLDS WITH ALTERNATIVE BINDING SURFACES | JANSSEN BIOTECH, INC. (US) | 2013-04-04 | — | — | WO | disclosed |
| US-20130079243-A1 | Fibronectin Type III Repeat Based Protein Scaffolds with Alternative Binding Surfaces | JANSSEN BIOTECH, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| EP-2571531-A2 | STABILIZED FIBRONECTIN DOMAIN COMPOSITIONS, METHODS AND USES | Janssen Biotech, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| US-20110274623-A1 | Stabilized Fibronectin Domain Compositions, Methods and Uses | JANSSEN BIOTECH, INC. | 2011-11-10 | — | — | US | disclosed |
| WO-2011137319-A2 | STABILIZED FIBRONECTIN DOMAIN COMPOSITIONS, METHODS AND USES | CENTOCOR ORTHO BIOTECH INC. (US) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932680-B2 | CD8A-binding fibronectin type III domains | FN1, CD81, CD69 | LMNA 1124/4885ALDH1A1 4684/4885PDE7A 3558/4885 |
| US-12037379-B2 | CD71 binding fibronectin type III domains | CD63, FN1, CDV3 | LMNA 2904/4885ALDH1A1 4190/4885PDE7A 3050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.